Home › Compound Library › Vitamin E (Alpha-Tocopherol)

Vitamin E (Alpha-Tocopherol)

Vitaminoral · inferred

Fat-soluble antioxidant that protects cell membranes from oxidative damage. Liver continuously resecretes RRR-alpha-tocopherol to maintain plasma levels.

Projected serum levels — 400 IU (≈ 268 mg), once daily

Vitamin E (Alpha-Tocopherol)
Vitamin E (Alpha-Tocopherol) modeled serum levels, 400 IU (≈ 268 mg) once daily over 16 days Population-based pharmacokinetic estimate. Steady state reached after approximately 6 days. 0 62.5 125 188 250 Day 0 Day 4 Day 8 Day 12 Day 16 Time on a regular schedule ≈ steady state · day 6
Vitamin E (Alpha-Tocopherol) modeled serum levels with a loading dose of 1.2k IU, then 400 IU (≈ 268 mg) once daily The first dose is larger so levels approach steady state faster. 0 62.5 125 188 250 Day 0 Day 4 Day 8 Day 12 Day 16 Time on a regular schedule

Maintenance schedule: 400 IU (≈ 268 mg) once daily (oral).

Loading schedule: 1.2k IU on day 1, then 400 IU (≈ 268 mg) once daily — reaching therapeutic levels sooner.

Modeled steady state after ~6 days: peak ≈ 245 mg, trough ≈ 195 mg body load. Population-based estimate over 16 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Vitamin
Route modeled
Oral
Model confidence
inferred
Half-life
2 days
Common dose
400 IU (≈ 268 mg)
Suggested maximum
1k IU/day
Reference dose range
200–1k IU (single dose)
Suggested cadence
once daily
Validated against
267 mg oral — Cmax 11 mg/L at 10 h

Documented interactions

  • danger
    Levothyroxine (Synthroid) + Vitamin E (Alpha-Tocopherol) Protein binding

    Vitamin E (Alpha-Tocopherol) may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free…

  • danger
    Warfarin (Coumadin) + Vitamin E (Alpha-Tocopherol) Protein binding

    Vitamin E (Alpha-Tocopherol) may displace Warfarin (Coumadin) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free…

  • warning
    Apigenin + Vitamin E (Alpha-Tocopherol) Protein binding

    Apigenin may displace Vitamin E (Alpha-Tocopherol) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Aripiprazole (Abilify) + Vitamin E (Alpha-Tocopherol) Protein binding

    Aripiprazole (Abilify) may displace Vitamin E (Alpha-Tocopherol) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Armour Thyroid (Desiccated Thyroid Extract) + Vitamin E (Alpha-Tocopherol) Protein binding

    Vitamin E (Alpha-Tocopherol) may displace Armour Thyroid (Desiccated Thyroid Extract) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Aspirin (Acetylsalicylic Acid) + Vitamin E (Alpha-Tocopherol) Potentiation

    Vitamin E has antiplatelet activity. Combined with aspirin, bleeding risk is significantly increased.

Serum checks 258 modeled interaction pairings for vitamin e (alpha-tocopherol) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Alpha-tocopherol: roles in prevention and therapy of human disease Tucker JM, Townsend DM · Biomedicine & Pharmacotherapy, 2005 DOI

    Mechanistic and clinical review of alpha-tocopherol as the principal lipid-phase chain-breaking antioxidant in human membranes. It also reviews the mixed clinical-trial record and emphasizes that biochemical antioxidant…

  2. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality Miller ER et al. · Annals of Internal Medicine, 2005 DOI

    Meta-analysis of 19 trials found that high-dose vitamin E (400 IU/day or more) may increase all-cause mortality, suggesting lower doses are preferable.

  3. Vitamin E supplementation and cardiovascular events in high-risk patients (HOPE study) Yusuf S et al. · New England Journal of Medicine, 2000 DOI

    Large RCT of 9,541 high-risk patients found vitamin E 400 IU/day did not reduce cardiovascular events or cancer, establishing that supplementation does not prevent heart disease.

  4. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study Lee IM et al. · JAMA, 2005 DOI

    RCT of 39,876 women found vitamin E supplementation (600 IU every other day) did not prevent cancer or major cardiovascular events but reduced cardiovascular death by 24%.

6 published studies referenced in the app, each with a plain-language summary.